Sentinel Research, Communication Transparency Needed, GSK’s Troy Urges

FDA needs a more open, transparent process for developing plans for drug safety studies in its Sentinel electronic data surveillance project as well as for announcing results, GlaxoSmithKline Senior VP and General Counsel Daniel Troy urged during a conference on Sentinel Jan. 12.